SCHEMBL347626

SCHEMBL347626

O=C1OC2(c3cc(Cl)c(O)c(Cl)c3Oc3c2cc(Cl)c(O)c3Cl)c2c(Cl)ccc(Cl)c21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 3/20 0.50
RECQL P46063 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MEN1 O00255 2/20 0.50
BLM P54132 2/20 0.50
KMT2A Q03164 2/20 0.50
HPGD P15428 2/20 0.50
BRCA1 P38398 2/20 0.50
HSD17B10 Q99714 2/20 0.50
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
CASP1 P29466 1/20 0.50
HIF1A Q16665 1/20 0.50
GLB1 P16278 1/20 0.50
CTRC Q99895 1/20 0.50
SMAD3 P84022 1/20 0.50
DHFR P00374 5/20 0.39
TYMS P04818 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5146060 0.89 HPGD (0.50) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL8034668 0.86 TDP1 (0.45) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL204164 0.82 ALDH1A1 (0.48) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL202598 0.82 ALDH1A1 (0.48) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL29024627 0.81 THRB (0.72) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL18171688 0.80 ALDH1A1 (0.44) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL1689593 0.77 ALDH1A1 (0.44) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL29486978 0.77 MEN1 (0.61) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL498286 0.77 MEN1 (0.61) THRBRECQLTDP1ALDH1A1MEN1
SCHEMBL12836277 0.76 THRB (0.36) THRBRECQLTDP1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021011850-A2 AMPLIFICATION ASSAY FOR THE DETECTION OF ANAPLASMA PHAGOCYTOPHILUM CHAO CHIEN CHUNG (US) 2021-01-21 WO claimed
WO-2017124054-A1 METHODS AND REAGENTS FOR DETECTION OF CHIKUNGUNYA VIRUS AND ZIKA VIRUS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-07-20 WO claimed
US-9587271-B2 Mixtures for assaying nucleic acid, novel method of assaying nucleic acid with the use of the same and nucleic acid probe to be used therefor NIPPON STEEL & SUMIKIN ECO-TECH CORPORATION (JP) 2017-03-07 US claimed
EP-2904120-A1 METHODS AND REAGENTS FOR DETECTION, QUANTITATION, AND SEROTYPING OF DENGUE VIRUSES The Board of Trustees of The Leland Stanford Junior University (US) 2015-08-12 EP claimed
WO-2014055746-A1 METHODS AND REAGENTS FOR DETECTION, QUANTITATION, AND SEROTYPING OF DENGUE VIRUSES THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2014-04-10 WO claimed
US-8551706-B2 Identification of oligonucleotides for the capture, detection and quantitation of West Nile Virus NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2013-10-08 US claimed
EP-1552022-B1 IDENTIFICATION OF OLIGONUCLEOTIDES FOR THE CAPTURE, DETECTION AND QUANTITATION OF HEPATITIS A VIRAL NUCLEIC ACID NOVARTIS VACCINES & DIAGNOSTIC (US) 2013-01-23 EP claimed
US-20120219941-A1 Identification of Oligonucleotides for the Capture, Detection and Quantitation of Hepatitis A Viral Nucleic Acid CHIRON CORPORATION 2012-08-30 US claimed
US-20120015345-A1 Identification of Oligonucleotides for the Capture, Detection and Quantitation of West Nile Virus NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2012-01-19 US claimed
US-20110150911-A1 Methods and reagents for treating, preventing and diagnosing bunyavirus infection NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2011-06-23 US claimed
US-20070128637-A1 Identification of oligonucleotides for the capture, detection and quantitation of West Nile virus NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2007-06-07 US claimed
US-20050032729-A1 Identification of oligonucleotides for the capture, detection and quantitation of West Nile virus CHIRON CORPORATION 2005-02-10 US claimed
US-20030175698-A1 Retrovirus-specific oligonucleotides and a method for measuring retroviral titer using same VIROMED, CO., LTD. (KR) 2003-09-18 US claimed
US-20030143527-A1 Identification of oligonucleotides for the capture, detection and quantitation of hepatitis B viral DNA SHYAMALA VENKATAKRISHNA (US) 2003-07-31 US claimed
WO-2002090587-A1 RETROVIRUS-SPECIFIC OLIGONUCLEOTIDES AND A METHOD FOR MEASURING RETROVIRAL TITER USING SAME VIROMED CO., LTD. (KR) 2002-11-14 WO claimed
EP-0904411-B1 PASSIVE INTERNAL REFERENCES FOR THE DETECTION OF NUCLEIC ACID AMPLIFICATION PRODUCTS PE CORP NY (US) 2001-11-14 EP claimed
US-6180349-B1 AMPLIFICATION; CALIBRATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-01-30 US claimed
EP-0904411-A1 PASSIVE INTERNAL REFERENCES FOR THE DETECTION OF NUCLEIC ACID AMPLIFICATION PRODUCTS The Perkin-Elmer Corporation (US) 1999-03-31 EP claimed
US-5736333-A INTERNAL REFERENCE MOLECULE COMPRISING FIRST AND SECOND FLUOROPHORES JOINED BY NONHYBRIDIZING BACKBONE CONNECTOR WHICH PERMITS THE TRANSFER OF ENERGY FROM ONE TO THE OTHER THE PERKIN-ELMER CORPORATION (US) 1998-04-07 US claimed
WO-1997046708-A1 PASSIVE INTERNAL REFERENCES FOR THE DETECTION OF NUCLEIC ACID AMPLIFICATION PRODUCTS THE PERKIN-ELMER CORPORATION (US) 1997-12-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150911-A1 Methods and reagents for treating, preventing and diagnosing bunyavirus infection HAVCR2, MME, LGMN THRB 4405/4885RECQL 2121/4885TDP1 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.